Literature DB >> 29462060

Iliac Crest Bone Graft for Minimally Invasive Transforaminal Lumbar Interbody Fusion: A Prospective Analysis of Inpatient Pain, Narcotics Consumption, and Costs.

Brittany E Haws1, Benjamin Khechen, Ankur S Narain, Fady Y Hijji, Kaitlyn L Cardinal, Jordan A Guntin, Kern Singh.   

Abstract

STUDY
DESIGN: Retrospective Analysis OBJECTIVE.: The aim of this study was to determine whether an association between increased acute pain, postoperative time, and direct hospital costs exists between the use of iliac crest bone grafting (ICBG) and bone morphogenic protein (BMP)-2 following a primary, single-level minimally invasive transforaminal lumbar interbody fusion (MIS TLIF). SUMMARY OF BACKGROUND DATA: ICBG has been associated with enhanced fusion rates. Concerns have been raised in regards to increased operative time and postoperative pain. The advantages of ICBG compared to other spinal fusion adjuncts have been debated.
METHODS: Prospective, consecutive analysis of patients undergoing primary, single-level MIS TLIF with ICBG was compared to a historical cohort of consecutive patients that received BMP-2. Operative characteristics were compared between groups using χ analysis or independent t test for categorical and continuous variables, respectively. Postoperative inpatient pain was measured using the Visual Analog Scale, and inpatient narcotics consumption was quantified as oral morphine equivalents. Outcomes were compared between groups using multivariate regression controlling for preoperative characteristics.
RESULTS: A total of 98 patients were included in this analysis, 49 in each cohort. No significant differences were noted between cohorts with exception to sex (Females: ICBG, 53.06% vs. BMP-2, 32.65%, P = 0.041). There was a significant increase in operative time (14.53 minutes, P = 0.006) and estimated blood loss (16.64 mL, P = 0.014) in the ICBG cohort. Narcotics consumption was similar between groups on postoperative days 0 and 1. ICBG was associated with decreased total direct costs ($19,315 vs. $21,645, P < 0.001) as compared to BMP-2.
CONCLUSION: Patients undergoing MIS TLIF with ICBG experienced increases in operative time and estimated blood loss that were not clinically significant. Furthermore, iliac crest harvesting did not result in an increase in acute pain or narcotics consumption. Further follow-up is necessary to determine the associated arthrodesis rates and long-term outcomes between each cohort. LEVEL OF EVIDENCE: 3.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29462060     DOI: 10.1097/BRS.0000000000002599

Source DB:  PubMed          Journal:  Spine (Phila Pa 1976)        ISSN: 0362-2436            Impact factor:   3.468


  4 in total

1.  Biomechanical analysis of iliac crest loading following cortico-cancellous bone harvesting.

Authors:  Paul Schmitz; Christoph Cornelius Neumann; Carsten Neumann; Michael Nerlich; Sebastian Dendorfer
Journal:  J Orthop Surg Res       Date:  2018-05-09       Impact factor: 2.359

2.  Allogenic Stem Cells in Spinal Fusion: A Systematic Review.

Authors:  Patrick C Hsieh; Zorica Buser; Andrea C Skelly; Erika D Brodt; Darrel Brodke; Hans-Joerg Meisel; Jong-Beom Park; S Tim Yoon; Jeffrey C Wang
Journal:  Global Spine J       Date:  2019-05-08

3.  Evaluation of the optimal dosage of BMP-9 through the comparison of bone regeneration induced by BMP-9 versus BMP-2 using an injectable microparticle embedded thermosensitive polymeric carrier in a rat cranial defect model.

Authors:  Bipin Gaihre; Angshuman Bharadwaz; Janitha M Unagolla; Ambalangodage C Jayasuriya
Journal:  Mater Sci Eng C Mater Biol Appl       Date:  2021-06-10

4.  Efficacy of Biocage in treating single-segment lumbar degenerative disease in patients with high risk of non-fusion: a prospective controlled study with at least 2 years' follow-up.

Authors:  Yang Li; Yang Yu; Tian-Yong Hou; Ze-Hua Zhang; Jun-Chao Xing; Hong-Wei Lu; Rui Zhou; Peng Cheng; Jian-Zhong Xu; Wen-Jie Wu; Fei Luo
Journal:  J Int Med Res       Date:  2020-09       Impact factor: 1.671

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.